Nutra Pharma Corporation (NPHC) Expanding Its Reach in the Pharmaceutical Space
Nutra Pharma Corporation (OTCQB: NPHC) is actively pursuing growth plans that will bolster its core business while expanding its reach into vital commercial markets. A versatile biotechnology company, Nutra Pharma markets Nyloxin and Pet Pain-Away (homeopathic drugs that treat moderate-to-severe chronic pain in humans and pets, respectively) to the over-the-counter pain management market.
Millions of Americans suffer from persistent pain. From veterans to active-duty military personnel to civilians, the presence of chronic pain is a major factor in many lives and so is the search for a lasting cure. This is where Nutra Pharma comes in.
The company has developed pain-relief solutions that are both potent and long-lasting. They are non-opiate, non-narcotic and non-addictive. They are safe for vital organs, such as the stomach, liver and kidney, and they do not affect cognitive or motor skills unfavorably. By offering pain-relief solutions that counter the record levels of opioid abuse evidenced in society, as well as the dangers of abusing acetaminophen and non-steroidal anti-inflammatory drugs such as ibuprofen, Nutra Pharma is poised to impact a vast, global market and benefit from the resulting rewards.
With the recent expansion of its key personnel, including the addition of Tom Northrop as senior commercial development officer, Nutra Pharma is facing several promising stages of growth. Northrop is a member of Tri-State Capital Partners, a New York-based management advisory and investment firm that advises promising enterprises, and his involvement with Nutra Pharma signals Tri-State’s involvement as well.
Tri-State’s support comes part-and-parcel with management resources, strategy development and implementation expertise and capital funding knowledge. With this level of support, Nutra Pharma has the tools that will allow for its expansion into new markets, including an opportunity to spearhead novel marketing and promotional activities geared toward the elderly, aging athletes and healthcare, governmental and military entities. The company will also have an opening to focus on the completion of its scientifically-rigorous pain relief trials in multiple locations.
That is only the beginning. With Tri-State’s backing, Nutra Pharma will also have the resources to accelerate the development of its prescription drug candidates. Presently, the company is designing and developing treatments for multiple sclerosis, human immunodeficiency virus and adrenomyeloneuropath.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Nutra Pharma Corporation (OTCQB: NPHC) is actively pursuing growth plans that will bolster its core business while expanding its reach into vital commercial markets. A versatile biotechnology company, Nutra Pharma markets Nyloxin and Pet Pain-Away (homeopathic drugs that treat moderate-to-severe chronic pain in humans and pets, respectively) to the over-the-counter pain management market.
Millions of Americans suffer from persistent pain. From veterans to active-duty military personnel to civilians, the presence of chronic pain is a major factor in many lives and so is the search for a lasting cure. This is where Nutra Pharma comes in.
The company has developed pain-relief solutions that are both potent and long-lasting. They are non-opiate, non-narcotic and non-addictive. They are safe for vital organs, such as the stomach, liver and kidney, and they do not affect cognitive or motor skills unfavorably. By offering pain-relief solutions that counter the record levels of opioid abuse evidenced in society, as well as the dangers of abusing acetaminophen and non-steroidal anti-inflammatory drugs such as ibuprofen, Nutra Pharma is poised to impact a vast, global market and benefit from the resulting rewards.
With the recent expansion of its key personnel, including the addition of Tom Northrop as senior commercial development officer, Nutra Pharma is facing several promising stages of growth. Northrop is a member of Tri-State Capital Partners, a New York-based management advisory and investment firm that advises promising enterprises, and his involvement with Nutra Pharma signals Tri-State’s involvement as well.
Tri-State’s support comes part-and-parcel with management resources, strategy development and implementation expertise and capital funding knowledge. With this level of support, Nutra Pharma has the tools that will allow for its expansion into new markets, including an opportunity to spearhead novel marketing and promotional activities geared toward the elderly, aging athletes and healthcare, governmental and military entities. The company will also have an opening to focus on the completion of its scientifically-rigorous pain relief trials in multiple locations.
That is only the beginning. With Tri-State’s backing, Nutra Pharma will also have the resources to accelerate the development of its prescription drug candidates. Presently, the company is designing and developing treatments for multiple sclerosis, human immunodeficiency virus and adrenomyeloneuropath.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
